Skip to content

Study · Case report or series · n = 1 · 2023

1 result

Acute Pancreatitis in a Patient Taking Semaglutide.

Patel F, Gan A, Chang K, Vega KJ

Cureus19 Aug 2023Cited by 16 (Europe PMC)

PMID37731423 (opens in a new tab)PMCIDPMC10506915 (opens in a new tab)DOI10.7759/cureus.43773 (opens in a new tab)PepBankPUB-37731423
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. Though recent evidence suggests no increased risk of acute pancreatitis (AP) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with GLP-1 RAs. We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes. As GLP-1 RA use increases, clinicians should be aware of their potential to cause acute pancreatitis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A patient with type 2 diabetes developed acute pancreatitis after recently starting subcutaneous semaglutide.

    In plain wordsOne patient with type 2 diabetes developed acute pancreatitis soon after starting semaglutide injections.

    Peptide
    Semaglutide
    Outcome
    IncreaseAcute pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.